FDA 483 OBSERVATION · #64 OF 1,923 MOST-CITED

Training - Lack of or inadequate procedures

FDA cited this observation 383 times across 360 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA

Devices383

BY FISCAL YEAR

FY202613

FY202547

FY202438

FY202343

FY202242

FY202112

FY202027

FY201935

FY201842

FY201739

FY201645

What this observation means, and how to comply

SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.

21 CFR 820.25

The device manufacturer lacked adequate procedures to identify training needs and ensure personnel were trained to perform their assigned responsibilities, so staff may have performed GxP tasks without demonstrated competence.

Why FDA writes it — People execute every quality control the system defines. Untrained personnel — especially where errors have quality or safety consequences — is a direct route to defects, so FDA cites inadequate training as a first-order systemic weakness.

HOW TO COMPLY

Establish procedures for identifying training needs and ensuring all personnel are trained to adequately perform their assigned responsibilities.
Make personnel aware of device defects that may occur from improper performance of their jobs, and of the consequences of their errors.
Train those performing verification and validation activities in the defects and errors they may encounter.
Document training and keep records current.

WHY FIRMS GET CITED

Training recorded as one-time onboarding and never refreshed as roles or procedures change.
No linkage between the task’s quality risk and the training required for it.

PROFESSIONAL · REMEDIATION PLAYBOOK · SPEQ SYNTHESIS

How to close this finding — and stop it recurring

CHECKING ACCESS

Checking your Professional access…

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.8× the rate of the average FDA-cited firm (13.9% vs 7.8%), across 360 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…